Cnicin Attenuates Aluminium Chloride–Induced Neurodegeneration Through Antioxidant and Anti-Inflammatory Mechanisms Authors: Li Yu, Wardah A. Alhoqail, Suresh Mickymaray, Fang Li Published: 2026 ABSTRACT BackgroundAlzheimer’s disease (AD) is a progressive neurodegenerative disorder with limited disease-modifying therapies. Aluminium chloride (AlCl3)-induced neurotoxicity mimics key pathological features of AD, including oxidative stress, neuroinflammation, and cholinergic dysfunction.ObjectiveThis study aimed to evaluate the neuroprotective effect of cnicin in an AlCl3-induced rat model of Alzheimer-like neurodegeneration.MethodsRats were divided into five groups: normal control, AlCl3 control (75 mg/kg/day, p.o.), AlCl3 with cnicin (20 and 40 mg/kg/day, p.o.), and AlCl3 with donepezil (5 mg/kg/day, p.o.) for 30 days. Behavioral performance was assessed using hanging wire and beam walking tests. Biochemical parameters, including acetylcholinesterase (AChE), antioxidant enzymes (SOD, CAT, GSH), malondialdehyde (MDA), and inflammatory cytokines (TNF-α, IL-1β) were analyzed, along with histopathology.ResultsAlCl3 administration induced significant behavioral deficits, increased AChE activity, oxidative stress, neuroinflammation, and neuronal damage. Cnicin treatment dose-dependently improved motor function, reduced AChE activity, restored antioxidant levels, decreased lipid peroxidation, and suppressed inflammatory markers. Histological analysis confirmed preservation of neuronal architecture, comparable to that of donepezil.ConclusionCnicin exhibits significant neuroprotective effects against AlCl3-induced neurodegeneration by modulating cholinergic activity, oxidative stress, and inflammation, suggesting its potential as a therapeutic agent for AD. Introduction Neurodegenerative diseases have become a significant and increasing global healthcare issue, with demographic shifts towards an older population being a primary causative factor. 1 The disorders are characterized as a heterogeneous group of persistent and progressive diseases, which are characterized by the gradual destruction of neuronal structure and function and are often accompanied by protein misfolding and aggregation, which ultimately result in neuronal dysfunction and cell death in the brain and spinal cord.2,3 Recent findings of the Global Burden of Disease (GBD) 2021 studies highlight that the disorders, including Alzheimer’s disease, Parkinson’s disease, and other dementias, represent a significant cause of mortality and disability in the world. 1 The World Health Organization has also estimated that neurodegenerative diseases will become the second largest cause of death in the world, following cardiovascular diseases. 4 Epidemiological statistics indicate that the occurrence of diseases increases exponentially, as Parkinson’s disease is already the most rapidly growing type of neurological condition in the world, and cases of dementia are expected to be almost three times higher by 2050, and the number of deaths caused by motor neuron diseases has a steady tendency to increase.5-7 In addition to causing mortality, the conditions are associated with high socioeconomic and healthcare costs, including prolonged disability, loss of independence, and widespread caregiving requirements. 8 Neurodegenerative diseases have become one of the leading global public health concerns of the 21st century, with their prevalence, progressive pathology, and minimal disease-modifying therapies, and this trend is expected to escalate alongside further rises in life expectancy.9,10 Current treatments for neurodegenerative diseases are generally symptomatic and do not have definitive disease-modifying efficacy.11,12 Approved treatments for AD involve primarily acetylcholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists, and PD is treated with monoamine oxidase-B inhibitors, levodopa, and dopamine agonists. Although these drugs provide temporary symptomatic benefit, their clinical use is restricted by their frequent adverse effects, including gastrointestinal disturbances and headache13-15 and poor CNS bioavailability due to a restrictive blood-brain barrier. 16 These limitations highlight the need for alternative therapeutic strategies that improve the delivery of drugs to the brain, eliminate toxicity, and address underlying disease pathology rather than its symptoms alone. Cnicin is a bioactive sesquiterpene lactone that is mostly isolated from plants of the Centaurea species, and has gained growing pharmaceutical attention for its broad spectrum of biological activities.17,18 The compound is known as one of the major bioactive components of C. benedictus that contributes to the plant’s traditional therapeutic uses.19,20 This bioactive compound exhibits a substantial inflammation attenuating activity through inhibition of NF-kappaB and iNOS. In addition to this, cnicin also exhibits significant cytotoxic effects on several cancer cell lines. 21 In silico studies support the pharmacological properties and the therapeutic value of cnicin, which validates traditional medicinal applications, while underscoring the potential of cnicin as a source for the development of new therapeutic compounds. 19 This study assessed the neuroprotective potential of cnicin in an aluminium chloride (AlCl3)–induced rat model of Alzheimer’s disease. Prolonged aluminium exposure disrupts calcium homeostasis, enhances oxidative stress, impairs cholinergic neurotransmission, and triggers neuroinflammatory responses, closely resembling key pathological features of Alzheimer’s disease.22,23 Consequently, the administration of AlCl3 is widely used for the induction of cognitive deficits, neuronal damage, and alterations of behavior in rodents, which provides a reliable and reproducible experimental model to study neurodegenerative diseases.24,25 This model has been widely validated for preclinical screening of neuroprotective agents against oxidative stress and inflammation induced by aluminium-induced neurotoxicity. 26 In this context, the present investigation was aimed at determining whether cnicin could attenuate AlCl3-induced cognitive impairment and alterations in neurochemical content, reinforcing its suitability as a prospective therapeutic candidate for the treatment of Alzheimer’s disease. Materials & Methods Experimental Animals This research was conducted in young male Wistar rats (180 - 220 g). The animals were obtained through a recognized supplier of laboratory animals, and kept in polypropylene cages in controlled conditions, with a constant temperature of 22 ± 2 °C, relative humidity of 50-60 percent, and a 12 h light/dark regime. An ad libitum supply of standard pellet diet and water was provided. Rats were acclimatized to the laboratory environment over a period of a week before the experiments could be initiated. The entire study, including acclimatization, the 30-day treatment regimen, and subsequent behavioral and biochemical analyses, was conducted between December 2025 and February 2026. Ethical Approval Details The study was designed, conducted, and reported in strict accordance with the ARRIVE guidelines to ensure transparency and reproducibility. The animal care procedures and experimental protocols were carried out following the guidelines and were sanctioned by the Institutional Animal Ethics Committee (IAEC). Research Design After a one-week acclimatization period, the animals were assigned to five experimental groups (n = 6 per group) using a computer-generated randomization sequence to ensure an unbiased distribution of subjects. Experimental neurotoxicity was induced by the oral administration of aluminum chloride (AlCl3) at a dose of 75 mg/kg body weight per day. The reference drug, donepezil, and the test compound, cnicin (purity: ≥90.0%; Sigma Aldrich, USA), were administered orally once daily, concurrent with AlCl3 administration, for a total duration of 30 days. Following the completion of the 30-day treatment regimen, behavioral assessments were conducted over three days (Day 31 to Day 33). To minimize environmental stress and anxiety, animals were handled gently and consistently by the same experimenter throughout the study duration. Furthermore, rats were monitored daily for physical and behavioral indicators of stress, including changes in fur quality (piloerection), posture, appetite, and activity levels, to ensure adherence to ethical standards and the reliability of experimental outcomes. The experimental grouping was as follows:• Group I (Normal Control): Received standard diet and distilled water for the duration of the study.• Group II (AlCl3 Control): Administered AlCl3 (75 mg/kg/day, p.o.) for 30 consecutive days.• Group III (Cnicin 20 mg/kg): Treated with AlCl3 (75 mg/kg/day, p.o.) in combination with cnicin (20 mg/kg/day, p.o.) for 30 days.• Group IV (Cnicin 40 mg/kg): Treated with AlCl3 (75 mg/kg/day, p.o.) in combination with cnicin (40 mg/kg/day, p.o.) for 30 days.• Group V (Donepezil): Treated with AlCl3 (75 mg/kg/day, p.o.) along with donepezil (5 mg/kg/day, p.o.) as the standard reference drug for 30 days. • Group I (Normal Control): Received standard diet and distilled water for the duration of the study. • Group I (Normal Control): Received standard diet and distilled water for the duration of the study. • Group II (AlCl3 Control): Administered AlCl3 (75 mg/kg/day, p.o.) for 30 consecutive days. • Group II (AlCl3 Control): Administered AlCl3 (75 mg/kg/day, p.o.) for 30 consecutive days. • Group III (Cnicin 20 mg/kg): Treated with AlCl3 (75 mg/kg/day, p.o.) in combination with cnicin (20 mg/kg/day, p.o.) for 30 days. • Group III (Cnicin 20 mg/kg): Treated with AlCl3 (75 mg/kg/day, p.o.) in combination with cnicin (20 mg/kg/day, p.o.) for 30 days. • Group IV (Cnicin 40 mg/kg): Treated with AlCl3 (75 mg/kg/day, p.o.) in combination with cnicin (40 mg/kg/day, p.o.) for 30 days. • Group IV (Cnicin 40 mg/kg): Treated with AlCl3 (75 mg/kg/day, p.o.) in combination with cnicin (40 mg/kg/day, p.o.) for 30 days. • Group V (Donepezil): Treated with AlCl3 (75 mg/kg/day, p.o.) along with donepezil (5 mg/kg/day, p.o.) as the standard reference drug for 30 days. • Group V (Donepezil): Treated with AlCl3 (75 mg/kg/day, p.o.) along with donepezil (5 mg/kg/day, p.o.) as the standard reference drug for 30 days. After the treatment regimen was completed, animals were then exposed to experimental tests as per the objectives of the study. Schematic illustration of the neuroprotective effects of cnicin against aluminium chloride (AlCl3)-induced Alzheimer-like neurodegeneration in rats (Figure 1).Figure 1.Schematic illustration of the neuroprotective effects of cnicin against aluminium chloride (AlCl3)-induced Alzheimer-like neurodegeneration in rats Schematic illustration of the neuroprotective effects of cnicin against aluminium chloride (AlCl3)-induced Alzheimer-like neurodegeneration in rats Assessment of Body Weight The body weight was also observed during the study and used as a measure of overall health and treatment effect. The measurements were taken to determine the effects of toxicity caused by aluminium chloride and the protective potentials of cnicin and the reference drug donepezil. Baseline body weight of each animal was established before the start of the drug administration through a calibrated digital balance, and the final body weight was measured at the end of the 30-day treatment. Hanging Wire Test The hanging wire test was used to measure neuromuscular performance and motor ability after the completion of the 30-day treatment regimen. 27 The experiment apparatus was made up of a metal wire mounted horizontally on an elevated platform 40 cm above a cushioned surface to avoid injury. Rats were then put on the wire with care, such that they could hold it using their forelimbs. The amount of time each animal was capable of holding onto the wire before falling was measured and noted as the hanging time in seconds. There was a maximum limit of cut-off time (30 s) to prevent excessive fatigue or stress. The rats were subjected to three independent trials, separated by a minimum rest period of 5 min, and the average hanging time was applied to the subsequent statistical analysis. Beam Walking Test At the conclusion of the experimental period, motor coordination and balance were measured with the help of the beam walking test. 28 The rats were conditioned to run on a higher wooden beam into a darkened goal box. Habituation was done during the two subsequent days before testing. During the test day, each animal was positioned at one end of the beam, and the time taken to cross the beam (crossing time) and the number of foot slips that occurred while crossing the beam were measured. All the rats were made to go through three trials, and the average of the values was analyzed. Inter-trial cleaning of the beam surface was done to remove olfactory prompts. Determination of Acetylcholinesterase Activity The activity of acetylcholinesterase (AChE) in the rat brain tissue was determined using a commercial colorimetric assay kit in line with the provided guidelines (Abcam, USA). The animals were humanely euthanized at the study’s end, and the brain tissues were quickly removed. Ice-cold phosphate-buffered saline was used to wash the brain tissues and stored in -80 °C until analysis. The assay buffer provided with the kit was used to homogenize the tissues under cold conditions and centrifuged at 10,000 × g within 15 min at 4 °C to acquire clarified supernatants. The activity of the enzyme was determined by placing the samples of supernatant in a 96-well microplate and incubating them with acetylthiocholine substrate and chromogenic substances. The development of color was determined by the use of a microplate reader in which the absorbance at 412 nm was measured. The activity of AChE was calculated by using a standard calibration curve and then adjusted to the total concentration of protein. Each measurement was repeated thrice. Estimation of Oxidative Stress Markers in Rat Brain Tissue The rat brain tissue was washed with ice-cold saline and homogenized in chilled phosphate buffer (0.1 M, pH 7.4). The centrifugation of the homogenates was performed at 10,000 × g after 15 min at 4 °C, and the supernatants were subjected to biochemical analysis. The levels of superoxide dismutase (SOD), reduced glutathione (GSH), catalase (CAT), and malondialdehyde (MDA) were determined by the use of commercially available colorimetric assay kits, according to the procedures provided by the manufacturer (Elabscience, USA and LS Bio, USA). The activity of SOD was assessed based on suppression of chromogenic reduction by superoxide, levels of GSH by use of thiol-specific color development, CAT by use of hydrogen peroxide decomposition, and MDA by use of thiobarbituric acid-reactive substance formation. The absorbance at the recommended wavelengths was measured with a spectrophotometer, and the results obtained were calculated with standard curves where necessary. The activities of enzymes and the observed oxidative stress markers were standardized with respect to the content of proteins and reported in the respective units. The total protein content in the tissue homogenates was estimated using Lowry’s method, with bovine serum albumin (BSA) utilized as the standard for the calibration curve. Determination of Inflammatory Cytokines in Rat Brain Tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta) concentrations were determined using commercially available enzyme-linked immunosorbent assay (ELISA) kits according to the instructions of the manufacturers (MyBioSource, USA). In a brief manner, brain homogenate samples and reference standards were placed in antibody-coated wells in microplates to allow them to bind cytokines. Enzyme-conjugated detection antibodies were then added after the initial washing to eliminate unbound components, and then a chromogenic substrate was added to facilitate the development of color. This reaction was then terminated, and the absorbance at 450 nm was measured using a microplate reader. The concentrations of cytokines were calculated based on standard curves, divided by the total protein level, and presented as pg/mg of protein. The concentration of total proteins in each sample was determined by the Lowry method to ensure accurate normalization across groups. Histological Analysis Following euthanasia, brain tissues were harvested and processed for paraffin embedding. Coronal sections (4–5 μm) were stained with hematoxylin and eosin (H&E) for morphological evaluation. To ensure objective assessment and minimize observer bias, all histological slides were coded, and the microscopic examination was performed by a pathologist blinded to the experimental group assignments. Representative images were captured to document AlCl3-induced damage and the protective effects of cnicin. Statistical Analysis Data are presented as mean ± SD. For all biochemical assays and molecular estimations, samples obtained from each animal (n = 6 per group) were processed and analyzed in triplicate to ensure technical reproducibility. The reported values reflect the mean results of these technical replicates across the biological replicates within each cohort. The normality and homogeneity of variance for each dataset were verified using Shapiro-Wilk and Levene’s tests, respectively. Statistical significance was determined using one-way ANOVA followed by Tukey’s post hoc multiple comparison test, with a p-value of < 0.05 considered statistically significant. Results Effect of Cnicin on Body Weight The experimental groups did not have any statistically significant differences in initial body weight, which confirmed similar baseline conditions (Figure 2A). Conversely, rats fed on AlCl3 alone showed a significant decrease in body weight at the end of the feeding period, relative to the normal control group. The co-administration of cnicin reduced the weight loss caused by AlCl3, and this effect was more pronounced with an increase in dose, which implied that there was a definite dose-response relationship. The result was partial improvement at 20 mg/kg, and a more significant recovery in body weight was observed in the rats at 40 mg/kg. Equally, the donepezil treatment had a powerful restorative effect on body weight compared to the disease control group (Figure 2B).Figure 2.Effect of cnicin on body weight changes in aluminum chloride (AlCl3)–treated rats. Initial and final body weights were recorded before and after the 30-day treatment period. Group I: normal control; Group II: AlCl3 (75 mg/kg/day, p.o.); Group III: AlCl3 + cnicin (20 mg/kg/day, p.o.); Group IV: AlCl3 + cnicin (40 mg/kg/day, p.o.); Group V: AlCl3 + donepezil (5 mg/kg/day, p.o.). Data are expressed as mean ± SD (n = 6). *p < 0.05 compared with normal control; **p < 0.01 compared with AlCl3 control Effect of cnicin on body weight changes in aluminum chloride (AlCl3)–treated rats. Initial and final body weights were recorded before and after the 30-day treatment period. Group I: normal control; Group II: AlCl3 (75 mg/kg/day, p.o.); Group III: AlCl3 + cnicin (20 mg/kg/day, p.o.); Group IV: AlCl3 + cnicin (40 mg/kg/day, p.o.); Group V: AlCl3 + donepezil (5 mg/kg/day, p.o.). Data are expressed as mean ± SD (n = 6). *p < 0.05 compared with normal control; **p < 0.01 compared with AlCl3 control Effect of Cnicin on Hanging Wire Performance Figure 3 represents the changes in the performance of hanging wires measured in rats that were treated with experimental neurotoxicity or cnicin. The rats that were treated with aluminium chloride alone experienced a significant deterioration in the performance of the hanging wire tests as compared to normal controls, which is indicative of deteriorating neuromuscular activity. The treatment of cnicin caused progressive enhancement of hanging time as the doses were increased. There was a moderate improvement in animals treated with cnicin at the 20mg/kg dose, and a significant rise in the animals treated with cnicin at the 40mg/kg dose, which was observed over the AlCl3 control group. The donepezil group of animals exhibited a considerable increase in the hanging time relative to the disease control, with the results being similar to the higher-dose cnicin group.Figure 3.Effect of cnicin on neuromuscular function assessed using the hanging wire test in aluminum chloride (AlCl3)–treated rats. Hanging time (s) was measured at the end of the 30-day experimental period. Group I: normal control; Group II: AlCl3 (75 mg/kg/day, p.o.); Group III: AlCl3 + cnicin (20 mg/kg/day, p.o.); Group IV: AlCl3 + cnicin (40 mg/kg/day, p.o.); Group V: AlCl3 + donepezil (5 mg/kg/day, p.o.). Values are presented as mean ± SD (n = 6). *p < 0.05 versus normal control; **p < 0.01 versus AlCl3 control Effect of cnicin on neuromuscular function assessed using the hanging wire test in aluminum chloride (AlCl3)–treated rats. Hanging time (s) was measured at the end of the 30-day experimental period. Group I: normal control; Group II: AlCl3 (75 mg/kg/day, p.o.); Group III: AlCl3 + cnicin (20 mg/kg/day, p.o.); Group IV: AlCl3 + cnicin (40 mg/kg/day, p.o.); Group V: AlCl3 + donepezil (5 mg/kg/day, p.o.). Values are presented as mean ± SD (n = 6). *p < 0.05 versus normal control; **p < 0.01 versus AlCl3 control Effect of Cnicin on Beam Walking Performance The administration of aluminum chloride (AlCl3) resulted in profound changes to the beam walking performance, which showed poor motor coordination and balance (Figure 4). The rats in the AlCl3-treated group exhibited a significant number of foot slips and increased time during which they crossed the beam relative to the normal control group, indicating motor dysfunction caused by AlCl3. There was a dose-dependent effect of co-treatment with cnicin on beam walking performance. Animals treated with cnicin at 20 mg/kg experienced decreased foot slips and crossing time compared to the control group treated with AlCl3, which is evidence of partial recovery of motor coordination. It was observed that there was a stronger level of improvement in 40 mg/kg cnicin-treated rats, where the foot slips and crossing time were significantly reduced as compared to the 20mg/kg cnicin-treated group, indicating a better level of efficacy at the higher dose. The standard reference drug donepezil treatment led to a major normalization of beam walking parameters, with the values coming close to those of the normal control group.Figure 4.Effect of cnicin on beam walking performance in experimental rats. (A) Number of foot slips and (B) crossing time recorded during the beam walking test. Group I: normal control; Group II: AlCl3 control (75 mg/kg/day, p.o.); Group III: AlCl3 + cnicin (20 mg/kg/day, p.o.); Group IV: AlCl3 + cnicin (40 mg/kg/day, p.o.); Group V: AlCl3 + donepezil (5 mg/kg/day, p.o.). Values are presented as mean ± SD (n = 6). *p < 0.05 versus normal control; **p < 0.01 versus AlCl3 control Effect of cnicin on beam walking performance in experimental rats. (A) Number of foot slips and (B) crossing time recorded during the beam walking test. Group I: normal control; Group II: AlCl3 control (75 mg/kg/day, p.o.); Group III: AlCl3 + cnicin (20 mg/kg/day, p.o.); Group IV: AlCl3 + cnicin (40 mg/kg/day, p.o.); Group V: AlCl3 + donepezil (5 mg/kg/day, p.o.). Values are presented as mean ± SD (n = 6). *p < 0.05 versus normal control; **p < 0.01 versus AlCl3 control Modulatory Effect of Cnicin on Acetylcholinesterase Activity of AlCl3-Intoxicated Rats As shown in Figure 5, the activity of acetylcholinesterase (AChE) was increased tremendously in rats exposed to AlCl3 alone relative to the normal control, which indicates the impaired cholinergic activity. Cnicin treatment had a pronounced effect on restoring the AChE activity, and the levels of the activity decreased gradually as the dose of the drug increased, which indicates that the dose-response relationship was evident. The increased dose of cnicin resulted in a significant reduction in the AChE activity as compared to the AlCl3-treated animals. Likewise, the standard drug administration also led to a notable reduction in the levels of AChE in comparison to the disease control.Figure 5.Effect of cnicin on acetylcholinesterase (AChE) activity in AlCl3-exposed experimental groups. Group I: Normal control; Group II: AlCl3 (75 mg/kg/day, p.o.); Group III: AlCl3 + cnicin (20 mg/kg/day, p.o.); Group IV: AlCl3 + cnicin (40 mg/kg/day, p.o.); Group V: AlCl3 + donepezil (5 mg/kg/day, p.o.). Data are expressed as mean ± SD (U/mg protein). Statistical analysis was carried out using one-way ANOVA followed by post hoc comparison. p< 0.05 vs. Group I; p< 0.01 vs. Group III Effect of cnicin on acetylcholinesterase (AChE) activity in AlCl3-exposed experimental groups. Group I: Normal control; Group II: AlCl3 (75 mg/kg/day, p.o.); Group III: AlCl3 + cnicin (20 mg/kg/day, p.o.); Group IV: AlCl3 + cnicin (40 mg/kg/day, p.o.); Group V: AlCl3 + donepezil (5 mg/kg/day, p.o.). Data are expressed as mean ± SD (U/mg protein). Statistical analysis was carried out using one-way ANOVA followed by post hoc comparison. p< 0.05 vs. Group I; p< 0.01 vs. Group III Effect of Cnicin on Oxidative Stress Markers in Rat Brain The effect of Cnicin on the modulation of oxidative stress in rats intoxicated with AlCl3 was evaluated, and the findings are shown in Figure 6. The administration of aluminum chloride (AlCl3) resulted in a severe oxidative imbalance, which was highly amplified in the rat brain tissue, as evidenced by large declines in antioxidant enzyme functions and large increases in lipid peroxidation when compared to normal control conditions. AlCl3 treatment alone resulted in significant reductions in the levels of SOD, GSH, and CAT, with a large increase in the levels of MDA and oxidative stress in animals under AlCl3 treatments. The co-treatment with cnicin showed a dose-dependent recovery of antioxidant status. The rats that received cnicin 20 mg/kg demonstrated moderate enhancement in SOD, GSH, and CAT levels, accompanied by a subsequent decrease in MDA levels in comparison with the AlCl3-treated group. A stronger normalization of antioxidant enzymes and lipid peroxidation was observed in animals treated with 40 mg/kg cnicin. The standard reference drug donepezil treatment, to an extent, reversed the oxidative injury caused by AlCl3 and reinstated antioxidant enzyme functions and decreased the levels of MDA to normal control levels.Figure 6.Effect of cnicin on oxidative stress markers in the brain of AlCl3-treated rats. (A) Superoxide dismutase (SOD), (B) reduced glutathione (GSH), (C) catalase (CAT), and (D) malondialdehyde (MDA) levels in rat brain tissue. Group I: Normal control; Group II: AlCl3 (75 mg/kg/day, p.o.); Group III: AlCl3 + cnicin (20 mg/kg/day, p.o.); Group IV: AlCl3 + cnicin (40 mg/kg/day, p.o.); Group V: AlCl3 + donepezil (5 mg/kg/day, p.o.). Values are expressed as mean ± SD. Statistical analysis was performed using one-way ANOVA followed by a post hoc test. p< 0.05 vs. Group I; p < 0.01 vs. Group III Effect of cnicin on oxidative stress markers in the brain of AlCl3-treated rats. (A) Superoxide dismutase (SOD), (B) reduced glutathione (GSH), (C) catalase (CAT), and (D) malondialdehyde (MDA) levels in rat brain tissue. Group I: Normal control; Group II: AlCl3 (75 mg/kg/day, p.o.); Group III: AlCl3 + cnicin (20 mg/kg/day, p.o.); Group IV: AlCl3 + cnicin (40 mg/kg/day, p.o.); Group V: AlCl3 + donepezil (5 mg/kg/day, p.o.). Values are expressed as mean ± SD. Statistical analysis was performed using one-way ANOVA followed by a post hoc test. p< 0.05 vs. Group I; p < 0.01 vs. Group III Influence of Cnicin on Neuroinflammatory Markers When rats were subjected to aluminum chloride (AlCl3), there was evident inflammatory signaling in brain tissue as indicated by significantly higher tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β) levels compared to the normal control group (Figure 7). This increase was the most significant with the AlCl3-only group, which implies that a neuroinflammatory state was induced. Co-administration of cnicin and AlCl3 resulted in the gradual reduction of cytokines. A partial decrease in the level of TNF-a and IL-1β was observed with a lower concentration of cnicin (20mg/kg), but a significant positive result was observed when cnicin was used at a higher concentration of 40mg/kg. The values of the cytokines were significantly suppressed in animals treated with donepezil, and the values were almost similar to those of the normal control group.Figure 7.Modulatory effect of cnicin on inflammatory cytokines in the brains of AlCl3-treated rats. (A) Tumor necrosis factor-α (TNF-α) and (B) interleukin-1β (IL-1β) concentrations measured in rat brain homogenates. Group I: Normal control; Group II: AlCl3 (75 mg/kg/day, p.o.); Group III: AlCl3 + cnicin (20 mg/kg/day, p.o.); Group IV: AlCl3 + cnicin (40 mg/kg/day, p.o.); Group V: AlCl3 + donepezil (5 mg/kg/day, p.o.). Values are presented as mean ± SD and expressed as pg/mg protein. Statistical comparisons were performed using one-way ANOVA followed by post hoc analysis. p< 0.05 compared with Group I; p < 0.01 compared with Group III Modulatory effect of cnicin on inflammatory cytokines in the brains of AlCl3-treated rats. (A) Tumor necrosis factor-α (TNF-α) and (B) interleukin-1β (IL-1β) concentrations measured in rat brain homogenates. Group I: Normal control; Group II: AlCl3 (75 mg/kg/day, p.o.); Group III: AlCl3 + cnicin (20 mg/kg/day, p.o.); Group IV: AlCl3 + cnicin (40 mg/kg/day, p.o.); Group V: AlCl3 + donepezil (5 mg/kg/day, p.o.). Values are presented as mean ± SD and expressed as pg/mg protein. Statistical comparisons were performed using one-way ANOVA followed by post hoc analysis. p< 0.05 compared with Group I; p < 0.01 compared with Group III Histopathological Evaluation of Brain Tissue Histological analysis of hematoxylin and eosin-stained brain sections showed that there were significant group-related changes in the brain structure (Figure 8). The control group (7A) had a well-maintained brain structure and intact neuronal organization. The pyramidal and granule cell layers were closely packed and uniformly distributed and did not indicate any cellular degeneration or structural disturbance. On the contrary, rats that received aluminum chloride alone exhibited severe histopathological abnormalities. They were neuronal degeneration, a decrease in cellular density, disorganization of pyramidal and granule cell layers, and amplification of vacuolization, which demonstrated the existence of neurotoxic damage by AlCl3 (7B). The combination of cnicin with AlCl3 showed some histological improvement, with 20mg/kg Cnicin-treated animals demonstrating some partial restoration of brain architecture with less neuronal loss, and some moderate reorganization of cellular layers, but still with some mild degenerative changes (7C). A stronger protective effect was found in 40mg/kg Cnicin-treated animals, where the neurons were found to be largely preserved with enhanced cellular density and almost normal distribution of the pyramidal and granule layers (7D). AlCl3-induced histopathological changes were significantly reduced following treatment with the standard drug donepezil. The brain tissues section of this group showed clear neuronal layers and reduced structural abnormalities, and is similar to the normal control group (7E).Figure 8.Representative H&E-stained brain tissue sections showing intact neuronal architecture in the normal control. (A): Normal control; (B): AlCl3 (75 mg/kg/day, p.o.); (C): AlCl3 + cnicin (20 mg/kg/day, p.o.); (D): AlCl3 + cnicin (40 mg/kg/day, p.o.); (E): AlCl3 + donepezil (5 mg/kg/day, p.o.). Black arrows: neuronal degeneration; Blue arrows: Decreased cellular density; Green arrows: disorganization of pyramidal and granule cell layers; Yellow arrows: Amplification of vacuolization. Scale bar: 50 µm Representative H&E-stained brain tissue sections showing intact neuronal architecture in the normal control. (A): Normal control; (B): AlCl3 (75 mg/kg/day, p.o.); (C): AlCl3 + cnicin (20 mg/kg/day, p.o.); (D): AlCl3 + cnicin (40 mg/kg/day, p.o.); (E): AlCl3 + donepezil (5 mg/kg/day, p.o.). Black arrows: neuronal degeneration; Blue arrows: Decreased cellular density; Green arrows: disorganization of pyramidal and granule cell layers; Yellow arrows: Amplification of vacuolization. Scale bar: 50 µm Discussion Alzheimer’s disease (AD) is the most widespread type of dementia, which causes almost half to three-quarters of dementia cases worldwide, with prevalence rates rising significantly after age 65 years. 29 AD is clinically characterized by a progressive impairment of memory, cognition, and behavior, and these changes are accompanied by particular neuropathological changes, such as the presence of Aβ plaques and tau pathology.30,31 These characteristic changes are the result of a multifaceted and interdependent web of pathogenic processes, including oxidative stress, mitochondrial dysfunction, abnormal tau phosphorylation, Aβ aggregation, chronic neuroinflammation, and the dysfunction of cholinergic neurotransmission, which ultimately leads to synaptic dysfunction and neuronal loss.32,33 Although the disease pathology of AD has been studied, the existing treatments largely only alleviate symptoms and exhibit no ability to slow or prevent disease progression, which explains the importance of therapeutic agents that may mediate multiple pathways driving the disease.34,35 The degeneration of the cholinergic system is one of the key and therapeutically significant characteristics of the various pathogenic mechanisms involved in AD. Cholinergic neurons, including those located in the nucleus basalis of Meynert, are essential in the process of learning and memory formation and experience severe degeneration in the course of AD.36,37 This selective vulnerability is linked with close links to amyloid pathology, tau pathology, and long-term neuroinflammatory reactions, indicating that cholinergic dysfunction and classical AD neuropathology have a bidirectional relationship. 38 Altered cholinergic communication has been implicated in increased tau hyperphosphorylation, augmentation of inflammatory reactions, and initiation of apoptotic pathways, which increases cognitive decline, albeit incompletely comprehended on the molecular level. Therefore, the maintenance or rehabilitation of cholinergic neurotransmission remains a sensible and clinically promising therapeutic approach, which already supports the long-term relevance of the cholinergic hypothesis in AD.37,39 In that regard, the sesquiterpene lactone cnicin becomes a potential neurotherapeutic candidate. Clinically, cnicin has been shown to induce axonal regeneration in a variety of species, and one way it may do this is by suppressing vasohibins, which underscores its contribution to neuronal repair systems. 39 Notably, cnicin has desirable pharmacokinetic and safety properties, such as high oral bioavailability (84.7 percent in rats) and lack of an epoxy structure that can cause mutagenicity, which increases its drug development prospects. 40 Its low-dose efficacy in rodents and rabbits, as well as its lack of toxicity after high-dose intravenous use over an extended period, also indicate its translational potential. 41 In line with the above findings, in this study, cnicin treatment reversed weight loss caused by AlCl3, which is a systemic effect, implying safety. Besides, cnicin showed a significant effect on acetylcholinesterase (AChE) activity in AlCl3-exposed rats, which is one of the biochemical changes that occur in the pathogenesis of AD, which justifies its protective effect on cholinergic dysfunction and aluminum-induced neurodegeneration. Oxidative stress is one of the key pathogenic mechanisms in AD, which serves as a key connection between various processes related to the disease. 42 The metabolic needs of the brain and the high levels of lipids make it prone to oxidative damage.43,44 The overproduction of reactive oxygen species (ROS) causes oxidative alterations of neuronal lipids, proteins, and nucleic acids, which cause dysfunction and loss of synapses and neurons. 45 Oxidative stress also enhances the pathology of AD by contributing to Aβ aggregation and tau hyperphosphorylation, which is enhanced by mitochondrial dysfunction, metal deposition, chronic inflammation, and the inherent oxidative properties of the Aβ peptide. 46 The main risk factor of AD is aging, which enhances the presence of oxidative and inflammatory conditions and undermines the strength of endogenous antioxidant defenses, predisposing them to neurodegeneration. In line with this, antioxidant-based therapeutic interventions have been explored due to their possible effects in delaying or altering the disease progression.43,47 Simultaneously, chronic neuroinflammation plays a crucial role in AD disease progression. The deposition of Aβ triggers microglia, and this induces the release of pro-inflammatory cytokines such as TNF-α and IL-1β that can lead to neuronal injury and synaptic loss.48,49 Among them, the role of IL-1β is especially important, since it creates a vicious cycle of inflammation, which enhances the expression of abnormal neuronal activity and facilitates cellular death. 50 Although in the early stages, the acute neuroinflammatory reactions might promote the acquisition of the Aβs, the long-term stimulation of microglia and astrocytes increases the production of Aβs and tau, which leads to progressive neurodegeneration. 51 Interestingly, neuroinflammation is a frequently overlooked cause of AD that appears several years before the appearance of the clinical picture, which makes it a significant pathogenic agent and a therapeutic target. 51 Cnicin has been receiving growing interest due to its strong antioxidant and anti-inflammatory properties. It has been shown that cnicin has a strong anti-inflammatory potential with low micromolar IC 50 -values, as it suppresses inflammatory signals through the inhibition of nuclear factor-kB (NF-kB) activation and inducible nitric oxide synthase (iNOS). 52 In addition to its anti-inflammatory effects, cnicin has been reported to exert a variety of biological actions, such as cytotoxic activity against several cancer cell lines and antiviral activity against SARS-CoV-2, which highlights its multi-target pharmacological characteristics. 53 consistent with the prior literature, this research study revealed that cnicin significantly inhibited oxidative stress and neuroinflammatory reactions in an AlCl3-induced model of neurodegeneration, as indicated by the restoration of antioxidant defenses, reduction of lipid peroxidation, and suppression of TNF-α and IL-1β levels. These biochemical gains were supported by histopathological observations, which revealed maintenance of neuronal architecture and minimized tissue damage in cnicin-treated groups. Notably, the molecular and structural protection provided by cnicin was translated into meaningful functional recovery. The neuromuscular strength, balance, and motor coordination of the AlCl3-exposed rats were significantly impaired in hanging time when the rats were subjected to the wire hang test and foot slips as they crossed the beam walk test. The administration of cnicin greatly alleviated these behavioral impairments in a dose-dependent response, which replenished motor stamina and motor coordination. The noted behavioral performance improvements are most likely due to the effects of cnicin-mediated reduction of the oxidative stress, inhibition of long-term neuroinflammatory signaling, which jointly conserve neuronal integrity, synaptic performance, and sensorimotor integration. These observations combine to demonstrate that cnicin is not only able to reduce the biochemical and histopathological markers of AlCl3-induced neurodegeneration but also is capable of transferring such protective actions into meaningful behavioral changes, which highlights its potential as a treatment drug in the management of Alzheimer’s disease. Despite the significant neuroprotective findings observed in this investigation, several limitations must be acknowledged to provide a balanced context for the results. First, while the AlCl3-induced neurotoxicity model is a well-validated tool for screening neuroprotective agents, it may not fully encapsulate the complex, multifactorial pathophysiology and genetic components seen in clinical Alzheimer’s disease. Second, the study was restricted to young male Wistar rats, which precludes the assessment of age-dependent neurodegenerative changes and potential differences related to sexual dimorphism. Third, the current biochemical analysis focused primarily on broad markers of oxidative stress, cholinergic activity, and pro-inflammatory cytokines like TNF-α and IL-1β, rather than exploring specific downstream signaling pathways or gene expression profiles. Additionally, the 30-day duration of the treatment regimen provides insights into short-term preventive action but does not address the long-term efficacy or safety of chronic cnicin administration. Furthermore, the functional outcomes were limited to motor and coordination assessments, suggesting a need for more extensive cognitive testing in future protocols. These limitations will be comprehensively addressed in our future studies through the use of aged cohorts, diverse animal models, and more detailed molecular investigations to fully determine the translational potential of cnicin. Conclusion Altogether, the results of this study suggest that cnicin offers strong preventive action against aluminum chloride-induced neurodegenerative effects. Cnicin administration enhanced cholinergic control, improved antioxidant defense systems, and significantly decreased oxidative stress and pro-inflammatory signaling, leading to the preservation of neuronal integrity in the brain. These histological and biochemical changes were associated with significant improvements in motor strength, balance, and coordination, demonstrating that the neuroprotective effects of cnicin translate to functional outcomes within this neurotoxicity model. Comprehensively, the multi-pronged activities of cnicin highlight its potential as a neuroprotective candidate in attenuating neurodegenerative processes. While these findings align with mechanisms underlying conditions such as Alzheimer’s disease, future research on specific molecular targets and long-term efficacy in diverse models will be necessary to determine its translational potential.